A Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
Optimal Absorption of Omega-3Healthy
Interventions
DIETARY_SUPPLEMENT

life's Omega 1035DS

A natural triglyceride derived from microalgae with minimum 365 mg DHA, minimum 100 mg EPA, and minimum 520 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.

DIETARY_SUPPLEMENT

Fish Oil

Commercially available fish oil product MEG-3 1812 TG with a minimum 100 mg DHA/capsule, minimum 160 mg EPA/capsule, and minimum 300 mg/g DHA+EPA. Participants receive 600mg/d of omega-3 fatty acids from the fish oil.

OTHER

Placebo

The placebo capsules will be a mixture of corn and soybean oils. Participants receive 600mg/d of omega-3 fatty acids from the corn/soy placebo.

DIETARY_SUPPLEMENT

life's Omega O3020DS

A natural triglyceride derived from microalgae with minimum 210 mg DHA, minimum 300 mg EPA, and minimum 510 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.

Trial Locations (1)

4000

RDC Clinical, Brisbane

All Listed Sponsors
lead

RDC Clinical Pty Ltd

INDUSTRY